Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? (Q46062509)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? |
scientific article |
Statements
1 reference
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? (English)
1 reference
1 reference
David Marin
1 reference
Jamshid S Khorashad
1 reference
Letizia Foroni
1 reference
Dragana Milojkovic
1 reference
Alistair G Reid
1 reference
Katayoun Rezvani
1 reference
Marco Bua
1 reference
John M Goldman
1 reference
Jane F Apperley
1 reference
12 March 2009
1 reference
1 reference
145
1 reference
3
1 reference
373-375
1 reference
Identifiers
1 reference
1 reference